

have taken final action in the following case:

Ayman Saleh, Ph.D., University of Pittsburgh: Based on the report of an inquiry conducted by the University of Pittsburgh and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Dr. Saleh, former postdoctoral research associate, School of Medicine, University of Pittsburgh, engaged in scientific misconduct in research supported by the National Institutes of Health.

PHS finds that Dr. Saleh falsified:

(A) Data for a manuscript which purported to show Western blots of rabbit Bcl-2 and tubulin; the blots were actually obtained from different experiments by another researcher using antibody against Hsp70 and against Bag-1, respectively;

(B) The label on a Western blot for Bcl-2 that he presented to the inquiry committee as evidence that he had conducted the experiment at issue; the blot was actually from a different experiment by a coworker;

(C) Data for a laboratory figure purported to represent a rabbit PARP cleavage blot; the data was from another experiment, and the antibody to PARP was not available to Dr. Saleh at that time;

(D) Western blot data on pcasp-9 and p37/p35 for a manuscript on Hsp27; the data represented experiments that could not be performed because the cell lines were unavailable at the time; and

(E) Figure 2b, the panel that shows a Western blot of Casp-9(WT) in a publication by Srinivasa M. Srinivasula, Ramesh Hegde, Ayman Saleh, Pinaki Datta, Eric Shiozaki, Jijie Chais, Ryung-Ah Lee, Paul D. Robbins, Theresa Fernandes-Alnemri, Yigong Shi, and Emad S. Alnemri. "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis." *Nature* 410(6824):112-116, 2001. The Figure 2b data were actually taken from a Western blot of Bcl-XL data, in which Dr. Saleh transposed the lanes.

The experiments examined the regulation of programmed cell death (apoptosis), a process that is important to a better understanding of cancer. Figure 2b in the *Nature* paper represented a control experiment that confirmed the association of an X-linked gene to a particular type of apoptosis.

Dr. Saleh has entered into a Voluntary Exclusion Agreement with PHS in which he has voluntarily agreed for a period of three (3) years, beginning on May 3, 2001:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government

and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations);

(2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

Chris Pascal,

Director, Office of Research Integrity.

[FR Doc. 01-12681 Filed 5-18-01; 8:45 am]

BILLING CODE 4150-31-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Agency for Healthcare Research and Quality, HHS.

ACTION: Notice.

SUMMARY: This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request the Office of Management and Budget (OMB) to grant a "Voluntary Customer Satisfaction Survey Generic Clearance for the Agency for Healthcare Research and Quality." In accordance with the Paperwork Reduction Act of 1995, Public Law 104-13 (44 U.S.C. 3506(c)(2)(A)), AHRQ invites the public to comment on this proposed information collection request to allow AHRQ to conduct these customer satisfaction surveys.

DATES: Comments on this notice must be received by July 20, 2001.

ADDRESSES: Written comments should be submitted to: Cynthia D. McMichael, Reports Clearance Officer, AHRQ, 2101 East Jefferson Street, Suite 500, Rockville, MD 20852-4908.

All comments will become a matter of public record.

FOR FURTHER INFORMATION CONTACT:

Cynthia D. McMichael, AHRQ, Reports Clearance Officer, (301) 594-3132.

SUPPLEMENTARY INFORMATION:

Proposed Project

Voluntary Customer Satisfaction Survey Generic Clearance for the Agency for Healthcare Research and Quality

In response to Executive Order 12862, the Agency for Healthcare Research and Quality (AHRQ) plans to conduct voluntary customer satisfaction surveys to assess strengths and weaknesses in program services. Customer satisfaction surveys to be conducted by AHRQ may include readership surveys from individuals using AHRQ automated and electronic technology data bases to determine satisfaction with the information provided or surveys to assess effects of the grants streamlining efforts. Results of these surveys will be used in future program planning initiatives and to redirect resources and efforts, as needed, to improve AHRQ program services.

The current clearance will expire December 31, 2001. A generic approval will be requested from OMB to conduct customer satisfaction surveys over the next three years.

Method of Collection

The data will be collected using a combination of preferred methodologies appropriate to each survey. These methodologies are:

- Evaluation forms;
- Mail surveys;
- Focus groups;
- Automated and electronic technology (e.g., instant fax, on-line, feedback forms for AHRQ Clearinghouse Publications); and
- Telephone surveys.

The estimated annual hour burden is as follows:

Type of survey	Number of respondents	Average burden/response (hours per respondent)	Total hours of burden
Mail/Telephone Surveys	51,200	.15	7,680
Automated/ Web-based ..	52,000	.163	8,476
Focus Groups ..	200	1.0	200
Totals	103,400	.159	16,441

Request for Comments

Comments are invited on: (a) The necessity of the proposed collections; (b) the accuracy of the Agency's estimate of burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the

collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Copies of these proposed collection plans and instruments can be obtained from the AHRQ Reports Clearance Officer (see above).

Dated: May 10, 2001.

John M. Eisenberg,
Director.

[FR Doc. 01-12754 Filed 5-18-01; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Notice of Meetings

In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2), announcement is made of Special Emphasis Panel meetings.

A Special Emphasis Panel (SEP) is a committee of experts selected to conduct scientific reviews of applications related to their areas of expertise. The committee members are drawn from a list of experts designated to serve for particular individual meetings rather than for extended fixed terms of services.

Substantial segments of the upcoming SEP meetings listed below will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6). Grant applications are to be reviewed and discussed at these meetings. These discussions are likely to include personal information concerning individuals associated with these applications. This information is exempt from mandatory disclosure under the above-cited statutes.

1. *Name of SEP:* Centers of Excellence for Patient Safety Research and Practice.

Date: June 18-19, 2001 (Open on June 18 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

2. *Name of SEP:* Developmental Centers for Evaluation and Research in Patient Safety.

Date: June 20-21, 2001 (Open on June 20 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

3. *Name of SEP:* Primary Care PBRN: Competitive Continuations.

Date: July 13, 2001 (Open on July 13 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

4. *Name of SEP:* Building Research Infrastructure and Capacity (BRIC) Program.

Date: July 30-31, 2001 (Open on July 30 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

5. *Name of SEP:* Clinical Informatics to Promote Patient Safety RFA.

Date: August 2-3, 2001 (Open on August 2 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

6. *Name of SEP:* Improving Patient Safety: Health Systems Reporting, Analysis and Safety Improvement Research Demonstrations.

Date: August 6-7, 2001 (Open on August 6 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

7. *Name of SEP:* Patient Safety Research Dissemination and Education.

Date: August 16-17, 2001 (Open on August 16 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

8. *Name of SEP:* The Effect of Health Care Working Conditions on Quality of Care.

Date: August 23-24, 2001 (Open on August 23 from 8 a.m. to 8:15 a.m. and closed for remainder of the meeting).

Place: Four Point Sheraton Hotel, 8400 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland 20814.

Contact Person: Anyone wishing to obtain a roster of members of minutes of these meetings should contact Ms. Jenny Griffith, Committee management Officer, Office of Research Review, Education and Policy, AHRQ, 2101 East Jefferson Street, Suite 400, Rockville, Maryland 20852, Telephone (301) 594-1847.

Agenda items for these meetings are subject to change as priorities dictate.

Dated: May 14, 2001.

John M. Eisenberg,
Director.

[FR Doc. 01-12753 Filed 5-18-01; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Notice of Award of Non-Competitive Grant

AGENCY: Administration on Children, Youth and Families (ACYF)
Administration for Children and Families (ACF), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: Notice is hereby given that ACYF will award grant funds without competition to Western Kentucky University Head Start Quality Improvement Center (QIC) in the amount of \$300,000. This award is made to the QIC to further the provision of technical assistance services nationally to grantees and regional offices when they undertake the purchase, construction or major renovation of Head Start program facilities. The award will be made for the budget period beginning September 1, 2001 for a twelve month period, under existing grant award 90YQ0016.

Authority: This award will be made pursuant to the Head Start Act, amended, 42 U.S.C. 9801 et seq. (CFDA 93.600)

FOR FURTHER INFORMATION CONTACT:
Douglas Klafehn, Acting Associate Commissioner, Head Start Bureau, Administration for Children, Youth and Families, 330 C Street SW, Washington, D.C. 20447; (202) 205-8572.

Dated: May 15, 2001.

James A. Harrell,
Acting Commissioner, Administration on Children, Youth and Families.

[FR Doc. 01-12684 Filed 5-18-01; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food Safety Research: Availability of Cooperative Agreements; Request for Applications

AGENCY: Food and Drug Administration, HHS.